A Italiano


Affiliation: Institut Bergoni
Country: France


  1. Italiano A, Toulmonde M, Cioffi A, Penel N, Isambert N, Bompas E, et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol. 2012;23:1601-7 pubmed publisher
    ..Chemotherapy was associated with clinical benefit in 46% of patients with advanced WDLPS/DDLPS. OS remains poor, even though visceral metastatic disease is less frequent than in other sarcomas. ..
  2. Taieb S, Saada Bouzid E, Tresch E, Ryckewaert T, Bompas E, Italiano A, et al. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis. Eur J Cancer. 2015;51:202-9 pubmed publisher
    ..Dual size and tumour density assessment may be more suitable to evaluate responses to trabectedin in sarcoma patients as well as to improve the decision-making strategies for the continuation of trabectedin therapy. ..
  3. Monk B, Lorusso D, Italiano A, Kaye S, Aracil M, Tanovic A, et al. Trabectedin as a chemotherapy option for patients with BRCA deficiency. Cancer Treat Rev. 2016;50:175-182 pubmed publisher
  4. Italiano A, Bianchini L, Gjernes E, Keslair F, Ranchere Vince D, Dumollard J, et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res. 2009;15:5696-703 pubmed publisher
    ..Our goal was to determine whether the absence of CDK4 amplification was (a) correlated to a specific clinico-histopathologic profile; and (b) compensated by another genomic anomaly involving the CCND1/CDK4/P16INK4a/RB1/E2F pathway...
  5. Italiano A, Toulmonde M, Stoeckle E, Kind M, Kantor G, Coindre J, et al. Clinical outcome of leiomyosarcomas of vascular origin: comparison with leiomyosarcomas of other origin. Ann Oncol. 2010;21:1915-21 pubmed publisher
    ..1 versus 16.5 months, P = 0.84). Vascular origin is an independent adverse prognostic factor for MFS and OS in patients with LMS. Patients with metastatic vLMS had a similar outcome than patients with metastatic LMS of other origin. ..
  6. Italiano A, Toulmonde M, Bui Nguyen B. [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines]. Bull Cancer. 2010;97:679-86 pubmed publisher
    ..Further studies are needed in order to identify predictive factors of clinical benefit in advanced soft-tissue sarcoma patients treated with cytotoxic agents in combination or not with targeted therapies. ..
  7. Italiano A, Kind M, Stoeckle E, Jones N, Coindre J, Bui B. Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway. Anticancer Drugs. 2011;22:463-7 pubmed publisher
    ..Further investigations of the phosphoinositide 3-kinases/PTEN/Akt/mTOR pathway are needed to explore the role of mTOR inhibitors, either alone or in combination, in patients with advanced sarcoma. ..
  8. Italiano A, Cioffi A, Penel N, Levra M, Delcambre C, Kalbacher E, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2012;118:3330-6 pubmed publisher
    ..Cutaneous angiosarcomas respond favorably to weekly paclitaxel. Best supportive care should be considered in patients with poor PS. ..
  9. Italiano A, Chen C, Thomas R, Breen M, Bonnet F, Sevenet N, et al. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer. 2012;118:5878-87 pubmed publisher
    ..The scale of genetic abnormalities in these pathways remains unknown in angiosarcoma (AS)...

More Information


  1. Italiano A, Delva F, Mathoulin Pelissier S, Le Cesne A, Bonvalot S, Terrier P, et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol. 2010;21:2436-41 pubmed publisher
    ..8 (95% CI 0.5-1.2), P = 0.27; 5-year OS: 75% versus 65%, HR 0.8 (95% CI 0.6-1.1), P = 0.15]. This large cohort-based analysis with long-term follow-up indicates that patients with FNCLCC grade 3 disease may benefit from AC. ..
  2. Italiano A, Mathoulin Pelissier S, Cesne A, Terrier P, Bonvalot S, Collin F, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117:1049-54 pubmed publisher
    ..The objective of this study was to determine whether the overall survival of patients with metastatic soft tissue sarcoma (STS) has improved over the last 20 years...
  3. Italiano A, Thomas R, Breen M, Zhang L, Crago A, Singer S, et al. The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. Genes Chromosomes Cancer. 2012;51:569-78 pubmed publisher
    ..Thus, MYC amplification may play a crucial role in the angiogenic phenotype of AS through upregulation of the miR-17-92 cluster, which subsequently downregulates THBS1, a potent endogenous inhibitor of angiogenesis. ..
  4. Italiano A, Chen J, Zhang L, Hajdu M, Singer S, Dematteo R, et al. Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumours. Eur J Cancer. 2012;48:3215-22 pubmed publisher
    ..The IGF pathway is deregulated in GIST with distinct patterns according to age onset and mutational status. The IGF pathway may represent a therapeutic target in patients with primary or secondary resistance to imatinib. ..
  5. Italiano A, Penel N, Robin Y, Bui B, Le Cesne A, Piperno Neumann S, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol. 2009;20:425-30 pubmed publisher
    ..There are only scarce data about the benefit of adjunctive chemotherapy in patients with localized synovial sarcoma (SS)...
  6. Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol. 2010;17:1429-34 pubmed publisher
    ..The acquisition by metastases of a KRAS or a BRAF mutation that was not present in the PT is a rare event, occurring in 5% of cases of mCRC. This is not a frequent mechanism of primary resistance to anti-EGFR treatments in mCRC. ..
  7. Italiano A, Chen C, Sung Y, Singer S, Dematteo R, Laquaglia M, et al. SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors. BMC Cancer. 2012;12:408 pubmed publisher
    ..Although pediatric GIST consistently display alterations of SDHB protein expression, further molecular studies are needed to identify the crucial genes involved in their tumorigenesis. ..